Esperion Therapeutics (ESPR) Cost of Revenue (2020 - 2026)

Esperion Therapeutics' Cost of Revenue history runs 7 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• Quarterly Cost of Revenue rose 9.62% year-over-year to $34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.9 million (up 50.94% YoY) and the FY2024 annual result came in at $68.6 million, up 58.55% from the prior year.
• Cost of Revenue was $34.6 million for Q1 2026 at Esperion Therapeutics, down from $41.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $41.3 million in Q3 2025 and bottomed at $4.2 million in Q4 2022.
• A 5-year average of $17.2 million and a median of $12.5 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 409.78% — and 2023, when it declined 26.05%.
• Esperion Therapeutics' Cost of Revenue stood at $4.2 million in 2022, then jumped by 175.29% to $11.5 million in 2023, then soared by 123.81% to $25.6 million in 2024, then surged by 61.09% to $41.3 million in 2025, then decreased by 16.27% to $34.6 million in 2026.
• Business Quant data shows ESPR's Cost of Revenue at $34.6 million in Q1 2026, $41.3 million in Q3 2025, and $28.5 million in Q2 2025.